Avinger Future Growth

Future criteria checks 2/6

Avinger is forecast to grow earnings and revenue by 22.4% and 30.2% per annum respectively while EPS is expected to grow by 58% per annum.

Key information

22.4%

Earnings growth rate

58.0%

EPS growth rate

Medical Equipment earnings growth	16.8%
Revenue growth rate	30.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:AVGR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	18	-11	N/A	N/A	1
12/31/2025	14	-13	N/A	N/A	1
12/31/2024	7	-17	N/A	N/A	1
9/30/2024	7	-17	-15	-15	N/A
6/30/2024	7	-15	-15	-15	N/A
3/31/2024	8	-16	-15	-15	N/A
12/31/2023	8	-18	-14	-14	N/A
9/30/2023	8	-19	-14	-14	N/A
6/30/2023	8	-22	-14	-14	N/A
3/31/2023	8	-22	-15	-15	N/A
12/31/2022	8	-27	-17	-17	N/A
9/30/2022	9	-28	-18	-18	N/A
6/30/2022	9	-29	-18	-18	N/A
3/31/2022	9	-27	-17	-17	N/A
12/31/2021	10	-22	-16	-16	N/A
9/30/2021	10	-21	-15	-15	N/A
6/30/2021	10	-21	-15	-15	N/A
3/31/2021	9	-22	-15	-15	N/A
12/31/2020	9	-23	-15	-15	N/A
9/30/2020	9	-23	-15	-15	N/A
6/30/2020	9	-23	-16	-16	N/A
3/31/2020	10	-24	-16	-16	N/A
12/31/2019	9	-23	-17	-17	N/A
9/30/2019	9	-24	-17	-18	N/A
6/30/2019	8	-25	-17	-17	N/A
3/31/2019	8	-26	-18	-18	N/A
12/31/2018	8	-36	-18	-18	N/A
9/30/2018	8	-39	-20	-20	N/A
6/30/2018	8	-43	N/A	-24	N/A
3/31/2018	8	-49	N/A	-28	N/A
12/31/2017	10	-49	N/A	-34	N/A
9/30/2017	13	-52	N/A	-40	N/A
6/30/2017	16	-55	N/A	-44	N/A
3/31/2017	18	-55	N/A	-50	N/A
12/31/2016	19	-56	N/A	-53	N/A
9/30/2016	17	-56	N/A	-54	N/A
6/30/2016	15	-56	N/A	-55	N/A
3/31/2016	13	-53	N/A	-49	N/A
12/31/2015	11	-50	N/A	-41	N/A
9/30/2015	11	-44	N/A	-35	N/A
6/30/2015	11	-40	N/A	-28	N/A
3/31/2015	11	-37	N/A	-24	N/A
12/31/2014	11	-32	N/A	-22	N/A
9/30/2014	12	-32	N/A	-23	N/A
6/30/2014	12	-33	N/A	-27	N/A
3/31/2014	12	-37	N/A	-34	N/A
12/31/2013	13	-40	N/A	-41	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVGR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVGR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVGR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVGR's revenue (30.2% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: AVGR's revenue (30.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AVGR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 16:23
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avinger, Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marc Wiesenberger	B. Riley Securities, Inc.
Sean Lavin	BTIG
Jason Mills	Canaccord Genuity

Avinger Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Price target decreased to US$8.50

Consensus forecasts updated

Analysts increase EPS estimates to -US$0.69

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Insufficient new directors

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Consensus EPS estimates upgraded to US$3.59 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avinger GAAP EPS of -$0.94 beats by $0.15, revenue of $2.13M misses by $0.25M

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$8.50

Consensus forecasts updated

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Is Avinger (NASDAQ:AVGR) Using Debt Sensibly?

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

Is Avinger (NASDAQ:AVGR) A Risky Investment?

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Avinger shares fall after Q1 results fail to impress Wall Street

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Avinger Regains Compliance with Nasdaq Listing Requirements

Does Avinger (NASDAQ:AVGR) Have A Healthy Balance Sheet?

New 90-day high: US$0.89

Avinger 'Hot Penny Stock to buy' - Robinhood

New 90-day high: US$0.35

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Third quarter 2020 earnings released: US$0.079 loss per share

Revenue beats expectations, earnings disappoint

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$0.29